Amgen

Game-changing cholesterol-buster further reduces heart attack, strokeA new outcomes study shows that the PCSK9 inhibitor Repatha significantly reduced the risk of hard major adverse cardiovascular events in high-risk patients by 20%.
New bladder cancer, kidney disease therapies availableFDA recently approved 2 new therapies: an expanded drug indication for locally advanced or metastatic urothelial carcinoma (mUC) and a treatment for secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.
Novel drug reduces monthly migraine daysA global phase 3 study of erenumab (Amgen and Novartis) showed that the drug was able to prevent migraines headaches.
Clear skin within reach for psoriasis patientsNew data presented at the 25th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, this week shows that secukinumab (Cosentyx, Novartis) has long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis.
Biosimilars and interchangeable biologics: News to watchBiosimilars in the United States are slowly gaining traction, but widespread confusion and legal barriers remain.
Five specialty pharmaceutical trends to watchApprovals of specialty pharmaceuticals have far outpaced traditional drugs, and that trend will continue. But that’s not the only specialty medication trend that healthcare executives should have on their radar.
FDA approves biosimilar to HumiraFDA’s pace of biosimilar approvals is picking up, as it approved two major drugs for rheumatoid arthritis and other inflammatory diseases in the past month.
What the new biosimilar means for U.S. healthcarePhysicians and pharmacists welcomed FDA’s recent approval of etanercept-szzs (Erelzi), a biosimilar to Amgen’s top-selling Enbrel for rheumatoid arthritis, plaque psoriasis, and other inflammatory conditions.
New biosimilar for RA to save millionsFDA’s approval of a new biosimilar—the third FDA-approved biosimilar—stands to save the US healthcare system millions of dollars.
Remicade will now have a biosimilarExpert: Expectations are high that biosimilars can control overall biologic cost growth.